ACADIA Pharmaceuticals Inc.ACADNASDAQ
Loading
Year-over-year research & development expense growth
Latest
-3.50%
↓ 139% vs avg
Percentile
P41
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
9.04%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -3.50% |
| Q3 2025 | 12.67% |
| Q2 2025 | -0.40% |
| Q1 2025 | -22.30% |
| Q4 2024 | 51.23% |
| Q3 2024 | -12.63% |
| Q2 2024 | 27.74% |
| Q1 2024 | -10.58% |
| Q4 2023 | -57.48% |
| Q3 2023 | 167.08% |
| Q2 2023 | -15.00% |
| Q1 2023 | -8.71% |
| Q4 2022 | -6.88% |
| Q3 2022 | 7.52% |
| Q2 2022 | -41.29% |
| Q1 2022 | 92.49% |
| Q4 2021 | 14.30% |
| Q3 2021 | 2.86% |
| Q2 2021 | -0.07% |
| Q1 2021 | -8.28% |
| Q4 2020 | -48.27% |
| Q3 2020 | 86.77% |
| Q2 2020 | -11.48% |
| Q1 2020 | 26.28% |
| Q4 2019 | -8.15% |
| Q3 2019 | -6.98% |
| Q2 2019 | 27.20% |
| Q1 2019 | 9.84% |
| Q4 2018 | -9.28% |
| Q3 2018 | 13.99% |
| Q2 2018 | 18.63% |
| Q1 2018 | -9.04% |
| Q4 2017 | 18.56% |
| Q3 2017 | 6.56% |
| Q2 2017 | -3.47% |
| Q1 2017 | 17.18% |
| Q4 2016 | 17.07% |
| Q3 2016 | 26.05% |
| Q2 2016 | -10.09% |
| Q1 2016 | 11.28% |